Brought to you by:
Landmark BEST-CLI trial gains recognition as top cardiovascular advance in 2023
The American Heart Association (AHA) has named the BEST-CLI (Best endovascular vs. best surgical therapy in patients with critical limb ischemia) trial one of the top cardiovascular advances of 2023. This study—led by vascular surgeons Alik Farber, MD, and Matthew…
Make a ‘PLAN’ for CLTI by tuning into new webinar
An upcoming webinar is set to provide insights for healthcare professionals aiming to enhance their expertise in treating patients with chronic limb-threatening ischemia (CLTI). Titled “Structured Decision-Making in the CLTI Patient: Understanding the PLAN,” the webinar’s goal is to delve…
Breakthrough Device designation granted for Efemoral scaffold system designed to treat CLTI
Efemoral Medical has announced the granting of Food and Drug Administration (FDA) Breakthrough Device status for its novel Efemoral vascular scaffold system (EVSS) designed to treat de novo or restenotic lesions of the infrapopliteal arteries in patients with chronic limb-threatening ischemia (CLTI).…
The top 10 most popular Vascular Specialist stories of January 2024
In January, the most read stories from Vascular Specialist include a U.S. Aortic Research Consortium analysis of F/BEVAR preoperative risk factors in AAAs/TAAAs; a reflection on lessons learnt one year on from BEST-CLI; Southern Vascular’s election of its first female…
UK MHRA update: Paclitaxel-coated device increased mortality risk is withdrawn for PAD
Following a review, the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has updated guidance on the use of paclitaxel-coated devices stating that such devices can be considered for the treatment of peripheral arterial disease (PAD), including intermittent claudication and critical…
BEST-CLI: A year down the road
A dedicated session at the 2023 VEITHsymposium (Nov. 14–18) in New York City aimed to unpack the ways in which clinical practice and attitudes in the field of chronic limb-threatening ischemia (CLTI) have changed since the BEST-CLI trial was published…
SVS receives CMSS grant to advance diagnostic excellence
The Society for Vascular Surgery (SVS) has received a $100,000 grant from the Council of Medical Specialty Societies (CMSS) to promote diagnostic excellence across the medical field. The CMSS, a coalition of 53 specialty societies representing over 800,000 physicians, has…
Two-year SWING data ‘continue to show promise’ for sirolimus DCB in treating BTK disease
Two-year data from the SWING trial, a first-in-human study of the safety and performance of the Sundance sirolimus drug-coated balloon (DCB; Surmodics), have been presented at this year’s VEITHsymposium (Nov. 14–18) in New York City. The SWING trial is a…
PROMISE II 12-month data show durable outcomes with the LimFlow system in no-option CLTI patients
One-year results from the PROMISE II US pivotal trial demonstrate the durability of outcomes of transcatheter arterialisation of the deep veins (TADV) using the LimFlow system (LimFlow) and that the procedure is safe and reproducible. Daniel Clair (Vanderbilt University Medical…
The top 10 most popular Vascular Specialist stories of October 2023
Last month, the most popular stories from Vascular Specialist included The Centers for Medicare & Medicaid Services (CMS) confirmation of carotid artery stenting coverage expansion; data on a “next generation” inferior vena cava (IVC) filter retrieval device presented at the annual…